Compare VERU & ANGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | ANGH |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 33.8M |
| IPO Year | 1996 | 2021 |
| Metric | VERU | ANGH |
|---|---|---|
| Price | $2.09 | $3.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | ★ 106.8K | 16.2K |
| Earning Date | 12-16-2026 | 12-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,296,958.00 | N/A |
| Revenue This Year | N/A | $251.30 |
| Revenue Next Year | N/A | $26.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $2.25 |
| 52 Week High | $7.33 | $7.89 |
| Indicator | VERU | ANGH |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 45.85 |
| Support Level | $2.09 | $3.16 |
| Resistance Level | $2.68 | $3.87 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 26.67 | 39.02 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.